Pharmaceutical Companies

The approval provides consumers with an additional non-prescription option for managing common types of temporary pain.

Lytenava contains bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF) antibody that inhibits the growth of abnormal blood vessels that can damage the retina.

The agreements are nonexclusive and cover Aspen Pharmacare, Quality Chemical Industries and UCL Kenya in sub-Saharan Africa, as well as Aurobindo, Cipla, Emcure and Viatris in India.

Schizophrenia is a chronic and complex mental health disorder that can significantly affect patients, their families and caregivers when inadequately managed.

The approval follows a positive recommendation issued in April 2026 by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

The financing forms part of Biovac’s expansion programme, which aims to increase the company’s annual manufacturing capacity to as many as 500 million vaccine doses.

The latest decision marks another setback for amlitelimab, which Sanofi had previously positioned as a potential successor to Dupixent, its best-selling immunology asset.

The company plans to construct a new three-story, 145,000-square-foot facility for drug product manufacturing and packaging next to its existing operations.

The US Food and Drug Administration (FDA) approved Jideytro for adults with locally advanced or metastatic ROS1-positive NSCLC who have previously received treatment with a ROS1 kinase inhibitor.

Under the terms of the agreement, Lilly will pay US$6.75 per share in cash, representing a 40% premium over AtaiBeckley’s 30-day volume-weighted average share price.